Collectively, the results demonstrate that expression of E45K hRFC leads to increased MTX resistance due to decreased membrane transport and, secondarily, from alterations in binding affinities and transport of folate substrates. However, despite these findings, we could find no evidence of this mutation in 121 childhood ALL samples, suggesting that it does not contribute to clinical MTX resistance in this disease.
Introduction
The antifolate methotrexate (MTX) is a critical component of the therapy of pediatric acute lymphoblastic leukemia (ALL), the most common childhood cancer.
1,2 Current combination chemotherapy cures approximately 70% of children diagnosed with ALL, 3 however, the remaining 30% of patients typically succumb to the disease due to the emergence of drug-resistant cell populations. Resistance to MTX is an important cause of treatment failure in these children. 4 Mechanisms of MTX resistance include reduced drug transport; increased activity of the target enzyme, dihydrofolate reductase; structural alterations in dihydrofolate reductase, and decreased MTX polyglutamylation. 5 Defective MTX transport has been described commonly in ALL. [6] [7] [8] Cloning of the reduced folate carrier (RFC) gene, [9] [10] [11] [12] [13] encoding the major membrane transport protein for MTX, has permitted the characterization of molecular changes leading to defective MTX transport in resistant cells. The RFC is an integral membrane protein with 12 putative transmembrane domains. 9, 11, 14 A large number of RFC gene mutations leading to an antifolate-resistant phenotype have been described in rodent and human cell lines. [15] [16] [17] [18] [19] [20] [21] Although mutations have been identified throughout the RFC coding region, they appear to be disproportionately clustered within the first putative transmembrane domain (eg G44E, E45K, S46N, I48F). [16] [17] [18] [19] [20] 22 Of particular interest is E45K, originally identified in MTX-resistant murine cells 19 and, subsequently, in separate MTX-resistant CCRF-CEM human T-cell ALL sublines from our own 23 and another laboratory. 16 Upon transfection into MTXresistant L1210 cells, the murine E45K RFC results in the markedly increased uptake of reduced folates and folic acid compared to MTX. 19 Although there have been no reports of transfection of this mutation into human cells, qualitatively similar results were reported for the E45K human RFC (hRFC)-overexpressing CCRF-CEM subline (designated CEM/MTX-LF), selected in subphysiologic levels of reduced folates. 16 However, there were notable discrepancies between the transport parameters obtained with the murine RFC transfectants 19 and CEM/MTX-LF cells. 16 This may reflect species differences or, perhaps, the presence of additional gene alterations resulting from the low folate selection.
In this report, we stably transfected MTX-resistant CCRF-CEM cells (CEM/MTX R0) lacking a functional hRFC with wild-type and E45K hRFC constructs, in order to characterize the functional and metabolic consequences of E45K hRFC expression in an isogenic human leukemia cell background. In addition, we have assessed the possible clinical relevance of mutations in the first transmembrane domain of the hRFC, including the E45K mutation, in leukemic blasts isolated from bone marrow aspirates from children diagnosed with ALL.
Materials and methods

Cell lines and patient samples
All cell lines were maintained as suspension cultures in RPMI 1640 containing 2.3 M folic acid, supplemented with 10% fetal calf serum (FCS) (Life Technologies, Grand Island, NY, USA) and 2 mM L-glutamine at 37ºC in a humidified atmosphere of 5% CO 2 . Both CEM/MTX R 24 and CEM/MTX R0 sublines were independently derived from CCRF-CEM cells by stepwise exposure to increasing doses of MTX and were selected in final concentrations of 0.4 M MTX and 5 M MTX, respectively. For polyglutamylation, growth requirement and 3 H folic acid transport assays, cells were depleted of endogenous folates by growth in folate-free RPMI 1640 containing adenosine (60 M) and thymidine (10 M) supplemented with dialysed FCS (Life Technologies) and L-glutamine, as above. Routine screening for mycoplasma indicated that cell lines were free of contamination.
Bone marrow samples were obtained after informed consent from pediatric ALL patients presenting at Sydney Chil-dren's Hospital (Sydney, Australia) or from the Children's Hospital of Michigan and the Pediatric Oncology Group. Australian children were uniformly treated using the Australia and New Zealand Children's Cancer Study Group ALL Study V or Study VI protocol. 25 Patients presenting at American institutions were registered on the POG#8600 leukemia classification protocol and treated with the POG#8602 antimetabolite-based treatment protocol. 26 The diagnosis ALL specimens were those used in our previous studies of MTX response and resistance in pediatric ALL. 27 
Site-directed mutagenesis
Site-directed mutagenesis was performed using the Altered Sites II in vitro Mutagenesis Systems according to the manufacturer's instructions (Promega, Madison, WI, USA). Wildtype hRFC cDNA (KS43) 13 was excised from pcDNA3 and directionally ligated into pALTER-1 mutagenesis vector using KpnI and XbaI, the resultant construct designated pALT/RFC. Phosphorylated mutant sense oligonucleotide (5Ј-ACGGCCAGGGAAGAGCTTCA-3Ј) was annealed to alkaline denatured pALT/RFC, followed by mutant strand synthesis. An identical control reaction was performed with the pALTER-1 vector but in the absence of mutagenic oligonucleotide. Plasmid DNA was transformed initially into ES1301 mutS cells to allow replication of the mutant strand, followed by transformation into the more stable JM109 host strain. The presence of the E45K mutation was confirmed by XmnI digestion and cycle sequencing using the AmpliCycle sequencing kit (Perkin-Elmer, Branchburg, NJ, USA) according to the manufacturer's protocol. For transfection into mammalian cells, the E45K mutant hRFC was recloned into the pcDNA3 expression vector (Invitrogen, Carlsbad, CA, USA).
Electroporation
CEM/MTX R0 cells were transfected with either an empty-vector control, pcDNA3, the same vector containing wild-type hRFC cDNA, 13 or cDNA containing the E45K mutation. Logarithmically growing cells were harvested and resuspended in RPMI 1640 supplemented with 10% FCS (3 × 10 6 cells per 600 l medium) followed by addition of linearized plasmid DNA (50 or 100 g) and transferred to 0.4 cm electroporation cuvettes. The time taken from resuspension of cells to pulsing was no longer than 10 min. All manipulations were performed at room temperature. Cuvettes were pulsed once (Bio-Rad Gene Pulser, Sydney, Australia; 240 V, 960 F) and incubated at room temperature for 10 min prior to transfer to flasks containing RPMI 1640 (5 ml) supplemented with 20% FCS. After 36-48 h cellular debris was removed following low-speed centrifugation and remaining viable cells were plated in selection medium (1 ml/well) containing G418 (800 g/ml) in 24-well plates at Ϸ7.5 × 10 4 cells/well. Cells were re-fed every 4 days with 250 l/well of selection medium containing G418 at a concentration calculated for each time point as described by Xia and Liber. 29 Surviving cells in each well were counted via Trypan Blue exclusion on day 17 and harvested.
Northern analysis
Total RNA (20 g) isolated from cells was subjected to agarose gel electrophoresis and transferred on to a GeneScreen II Plus nylon membrane as previously described. 30 The membrane was probed with a 486 bp PCR product generated with hRFC forward primer, P1, 5Ј-AGGCACAGTGTCACC TTCGTC-3Ј and hRFC reverse primer, P2, 5Ј-CCGCACGAGA-GAGAAGATGT-3Ј. Labelling and hybridization of the probe, and membrane washes were performed essentially as described. 30 Membranes were rehybridized with a 32 P-labelled probe for the glyceraldehyde-3Ј-phosphate dehydrogenase (GAPDH) gene to ensure equal loading of lanes.
Membrane transport methodology
Initial uptake rates, measured at 37ºC over 180 s for 3 H MTX (0.5 M), and 300 s for 3 H folic acid (0.5 M), were determined as previously described 13,31 using 1-2 × 10 7 cells/ml. Cells were pre-incubated (15 min) with trimetrexate (1 M) prior to measurement of folic acid uptake. Kinetic constants (K t ,V max and K i ) were calculated as previously described.
13,32
Western analysis
Crude particulate membrane preparations of cells, separated on a 7.5% polyacrylamide gel, were probed with an anti-RFC antibody (1:2500 dilution), and goat anti-rabbit HRP-conjugated secondary antibody (Bio-Rad) (1:10000 dilution) as previously described. 33 For serial dilutions, protein was separated on 4-15% gradient gels (Bio-Rad) and probed with anti-RFC antibody (1:1000 dilution). hRFC protein was detected and imaged as previously described. 33 
Growth inhibition and growth requirement assays
Cells were grown in 96-well plates, exposed continuously to a range of concentrations of MTX, trimetrexate, raltitrexed, folic acid or 5-formyltetrahydrofolate for 72 h. Growth inhibition and growth requirement assays were performed in folate-replete and folate-free RPMI 1640, respectively. Cells grown in folate-free media were washed free of adenosine and thymidine prior to plating. Viabilities were determined by the addition of Alamar Blue (Astral Scientific, Serotec, CA, USA) as described 34 and calculations of ID 50 and EC 50 values and statistical analyses were performed as previously described.
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MTX polyglutamylation
MTX polyglutamylation was assessed by incubating cells, grown in either folate-replete or folate-free RPMI, with 3 H MTX (1 M) as previously described. 36 DNA sequencing of hRFC cDNAs were prepared from cell line and patient total RNAs 37 by reverse transcription using Moloney murine leukemia virus reverse transcriptase and random hexanucleotide primers 38 and were PCR amplified and sequenced with primers P1 and P2. cDNA products were digested with XmnI, separated on 12.5% polyacrylamide gels and stained with ethidium bromide. Genomic DNAs were amplified with hRFC specific primers RFC-P8, 5Ј-CAGTGTCACCTTCGTCCCCTCCG-3Ј; and RFCPolyJW, 5Ј-GGGTGATGAAGCTCTCCCCTGG-3Ј. Sequence analyses were done on an ABI Prism 377 automated sequencer (Perkin-Elmer, Norwalk, CT, USA).
Results
Transfection of wild-type and E45K hRFC cDNAs into MTX-resistant CEM/MTX R0 cells
In our previous report, we described markedly reduced MTX accumulation in highly drug-resistant CEM/MTX R cell. 6 Sequencing of the hRFC gene cDNA in these cells identified a heterozygous point mutation (G → A) at nucleotide 133, leading to the substitution of positively charged lysine for negatively charged glutamic acid at codon 45 ( Figure 1a ). This E45K mutation introduced a new XmnI restriction site, permitting its confirmation by XmnI digestion of the PCR-amplified hRFC cDNA fragment ( Figure 1b) .
To elucidate the contribution of the E45K hRFC mutation to the MTX-resistant phenotype of CEM/MTX R cells, the wildtype and mutant E45K hRFC cDNAs were transfected into an independently derived MTX-resistant cell line, CEM/MTX R0, by electroporation. CEM/MTX R0 cells were the first in a series of MTX-selected CCRF-CEM sublines that exhibited a profound MTX transport defect due to a truncating hRFC mutation. 15 The resulting sublines, designated CEM R0/V, CEM R0/RFC and CEM R0/E45K, for the empty-vector control, wild-type and E45K transfectants, respectively, were analyzed on Northern and Western blots (Figure 2 ). For both parental CCRF-CEM and CEM R0/V cells, hRFC transcripts and protein were low; however, for the CEM R0/RFC and CEMR0/E45K transfectants both hRFC transcripts and protein were dramatically elevated. For the Western blot, increases of 20-and 40-fold over parental cells were estimated (Table 1) .
MTX and folic acid uptake in hRFC transfected cells
Initial rates of 3 H MTX (0.5 M) uptake were assayed in parental CCRF-CEM cells and the transfected sublines (Figure 3a) . MTX uptake was negligible in CEM R0/V 'mock' transfected cells in close agreement with our inability to detect hRFC protein in these cells on Western blots (Figure 2b ). While influx was significantly restored for both the wild-type (CEM R0/RFC) and CEM R0/E45K transfectants, the levels were disproportionate to the expressed hRFC protein (Table 1) three-fold over parental cells (Figure 3a) accompanying an approximately 20-fold increase in hRFC protein. Whereas the influx rate for the CEM R0/E45K transfectants, expressing the mutant E45K hRFC, was approximately 50% that for the parental cells (Figure 3a) , this was accompanied by approximately 40-fold increased levels of hRFC protein (Table 1) . Kinetic constants for MTX uptake, summarized in Table 1 , were limited to the parental and the hRFC transfected sublines due to the low transport levels measured in the CEM R0/V emptyvector transfected cells. Only slight differences were calculated for both the K t and V max absolute values between the cell lines. However, when normalized for the amount of hRFC protein, the E45K transfected cells demonstrated less than 5% the V max transport rate of the CCRF-CEM cells and the V max (normalized)/K t value for MTX transport was only 2% that of CCRF-CEM cells. This suggests that there was a marked reduction in the efficiency of transport in the transfectant cell populations.
The hRFC transfectants were also examined for folic acid uptake (Figure 3b) . In striking contrast to the results obtained for MTX uptake, the CEM R0/E45K cells exhibited a six-fold increased rate of folic acid uptake relative to the parental CCRF-CEM cells. However, there were no significant differences in folic acid transport rates for wild-type transfectants or CEM/MTX R0 cells. This disparity was reflected in a decreased (10 to 12-fold) K i for folic acid in CEM R0/E45K cells, relative to CCRF-CEM cells and wild-type transfectants, as determined by Dixon analysis (Table 1) . A similar increase (9 to 18-fold) in binding of 5-formyl tetrahydrofolate in the CEM R0/E45K transfectants was recorded, as well (Table 1) .
Folate growth requirements and antifolate cytotoxicity assays of transfected cell populations
Both transfected cell lines were capable of growing on far lower concentrations of 5-formyl tetrahydrofolate and folic acid than parental CCRF-CEM cells (Table 2 ). This was particularly pronounced for the E45K hRFC transfected cells (CEM R0/E45K) for which the dramatically increased affinities of folic acid and 5-formyl tetrahydrofolate for the E45K hRFC over the wild-type transporter were accompanied by EC 50 values 189-and 170-fold, respectively, less than for the parental CCRF-CEM cells.
MTX cytotoxicity assays demonstrated a significant reversal of resistance in CEM R0/RFC and CEM R0/E45K cells, compared to CEM/MTX R0, and CEM R0/V cells (Table 3) . Nevertheless, four-fold and 28-fold MTX resistance was preserved in wild-type and mutant transfected cell populations, respectively, relative to parental CCRF-CEM cells (P Ͻ 0.001). An incomplete reversal of resistance to raltitrexed was, likewise, observed, however, for this agent, the difference between the transfected sublines was far greater (Table 3) . CEM R0/RFC cells showed a 2.5-fold resistance to raltitrexed while CEM R0/E45K remained approximately 500-fold resistant, compared to CCRF-CEM cells (P Ͻ 0.01). Interestingly, the wildtype and mutant transfectants were, respectively, 47-fold and 87-fold more resistant to the lipophilic antifolate, trimetrexate (P Ͻ 0.01). This difference in sensitivity could be substantially reduced (to 2.6-and 7.5-fold, respectively) when cells were previously depleted of endogenous folates and trimetrexate treatments were performed in the presence of 50 nM 5-formyl tetrahydrofolate (Table 4) .
Analysis of MTX polyglutamylation in transfected cells
The capacities of the transfected sublines to polyglutamylate MTX were examined for comparison with parental CCRF-CEM cells. In an initial experiment over 2 h with 5 M 3 H MTX, using cultures grown in standard media (ie 2.3 M folic acid), both the parental and CEM R0/RFC cells generated significant levels of MTX polyglutamates (mostly di-and triglutamates). However, only 3% of the MTX metabolites in CEM R0/E45K transfectants were polyglutamylated (all diglutamate) under these conditions (data not shown).
In subsequent experiments, 24 h treatments were used (with 1 M 3 H MTX), and incubations were performed on cells grown in either standard medium or folate-free medium (Figure 4 ) so as to assess the effects of exogenous folates on MTX polyglutamate synthesis. In these experiments, 89-95% of the MTX was polyglutamylated in both parental CCRF-CEM and CEM R0/RFC cells under folate-free and folate-replete conditions, with a nearly identical distribution among the dito pentaglutamate forms. Accumulations of both total cellular drug and polyglutamylated MTX were increased in CEM R0/RFC cells over parental CCRF-CEM cells approximately 30% in folate-replete and 70% in folate-free conditions. In the absence of folates, CEM R0/RFC cells accumulated approximately 40% more total drug and 50% more MTX polyglutamates than in folate-replete medium.
Total cellular accumulations of drug were almost identical between the CEM R0/RFC and CEM R0/E45K cells. Whereas 94% of intracellular MTX was polyglutamylated in CEM R0/E45K cells in folate-free medium, this was reduced to 71% in folate-replete conditions. Most significantly, growth in folate-free medium resulted in a 2.3-and three-fold increase in total and polyglutamylated MTX compared to that in standard folate conditions, with a 13.2-fold increase in the long chain length polyglutamates (glu4-5). The long-chain polyglutamyl forms represented 57% and 13% of polyglutamylated MTX, respectively, in folate-free and folate-replete conditions (Figure 4 ).
hRFC mutations in diagnosis and relapsed ALL
The incidence of mutations in the first transmembrane domain of the RFC (amino acids 28-48), 11 in general, and the inciLeukemia dence of the E45K mutation in particular in ALL samples at relapse (three T-cell and 17 B-precursor) was examined by automated DNA sequencing and XmnI restriction enzyme digestion, respectively. The E45K mutation was not identified in any of 20 relapse ALL specimens ( Figure 5 ) and no other sequence mutations were identified among amino acids 28 to 48 (data not shown). Similarly, automated sequencing of genomic DNAs prepared from 101 diagnosis (B-precursor) specimens failed to detect the E45K mutation (data not shown).
Discussion
The frequent occurrence of a G to A transition at codon 45 resulting in substitution of glutamate for lysine in RFCs in multiple MTX-resistant murine and human cell lines 16, 19, 23 suggests an essential structural or functional role for this amino acid in membrane transport. This issue was originally considered in transport impaired L1210 cells 19 transfected with the E45K murine RFC and, subsequently, in a CCRF-CEM subline (CEM/MTX-LF), selected in growth-limiting concentrations of folates to overexpress E45K hRFC. 16 However, attempts to generalize the results of these studies to the human transporter in cultured cells and patients receiving chemotherapy including antifolates are limited by (1) documented structural and functional differences between the murine and human RFC proteins, 39 (2) strong evidence that a number of adventitious enzyme alterations resulted from the low folate selection protocol used to generate the CEM/MTX-LF subline, 16 and (3) a complete lack of data on the occurrence of mutations in the first transmembrane domain of the hRFC, including E45K hRFC, in clinical specimens.
Following identification of an E45K mutant in our own MTX-resistant CEM/MTX R subline, 23 we stably transfected MTX-resistant CEM/MTX R0 cells with wild-type and E45K hRFC cDNA constructs so as to compare the functional and metabolic consequences of expressing the mutant transporter in an isogenic human leukemia cell background. High levels of both wild-type and E45K hRFCs were detected in plasma membranes of transfected CEM/MTX R0 cells by Western blotting, suggesting that there were no significant differences in targeting or stability between the carrier forms. 21, 40 Both transporters were functional, with overtly similar properties. There were minor differences in relative affinities for MTX binding (ie K t s) and in absolute rates of carrier translocation (V max ) between the transfected lines, and with parental CCRF-CEM cells, although they could largely be explained by the differences in levels of carrier expression (20-fold for CEM R0/RFC and 40-fold for CEM R0/E45K of parental levels). Thus, when initial uptake rates for MTX were normalized to hRFC levels on Western blots, V max (normalized)/K t uptake values ranged from 20% of parental levels for the wild-type hRFC transfectant (CEM R0/RFC) to 2% for the E45K hRFC (CEM R0/E45K). Furthermore, as the change in MTX K t for the CEM R0/E45K cells was small, the resistance to MTX on the basis of a transport defect is likely due to a marked reduction in the influx V max . Although V max for MTX was not measured directly in murine cells transfected with the E45K RFC, it was similarly concluded that the presence of the mutation limited the mobility of the carrier within the membrane. 19 Transport efficiency for both the wild-type and E45K hRFCs, therefore, clearly decreased at high levels of expression. Similar findings were previously reported in other human cells transfected with wild-type hRFC 33, 34 and may reflect roles for additional regulatory elements in hRFC function.
For the CEM R0/RFC transfectants, high levels of wild-type hRFC expression resulted in a near complete (within four-fold for MTX, 2.5-fold for raltitrexed) reversal of this highly resist- ) were incubated in the presence of 3 H MTX (1 M) for 24 h in either folate-replete (ie 2.3 M folic acid; white bars) or folate-free (black bars) RPMI. Amounts of MTX polyglutamates were determined as described in Materials and methods. Results represent the mean of three experiments. Total, total intracellular MTX; PGs, total polyglutamylated MTX; G1, native MTX; G2-G5, di-to penta-glutamylated MTX.
Leukemia ant phenotype. Resistance was much more pronounced for the CEM R0/E45K subline (28-fold for MTX, 495-fold for raltitrexed), even though net transport efficiency (ie not normalized for expression) was similar to, or only slightly decreased, from that for parental or wild-type levels. For trimetrexate, significant resistance resulted upon transfection with both the wild-type and E45K hRFC constructs, however, this was somewhat attenuated in the presence of decreased concentrations of media folate. As in previous studies of the E45K hRFC, 16 these paradoxical patterns of drug sensitivities are likely due to the selective increase in the rate of cellular uptake of 3 H folic acid by E45K hRFC over the wild-type carrier. For the E45K hRFC in our transfected cells, this was due to a 10 to 12-fold enhanced affinity for folic acid over MTX. Increased binding was also observed for 5-formyl tetrahydrofolate. The E45K hRFC transfectant also exhibited dramatically (189-and 170-fold, respectively) decreased growth requirements for both folic acid and 5-formyl tetrahydrofolate. Although similar results were reported for L1210 cells transfected with the murine E45K RFC, 19 for the mutated murine carrier, the magnitude of the differences from the wild-type L1210 transporter was far less pronounced, and the direction of the changes relative to sensitive parental cells differed (for 5-formyl tetrahydrofolate). The effects of increased folic acid transport on the level of drug resistance of the CEM R0/E45K cells to antifolate inhibitors is, presumably, due to direct competition for binding at their intracellular enzyme targets 41 and/or conversion to their polyglutamyl forms. 42 These effects would be particularly acute for raltitrexed, since synthesis of long chain polyglutamates is essential for the high affinity binding of this drug to thymidylate synthase, required for its cytotoxic activity. 43 It has been shown that for cells selected for resistance to 5,10-dideazatetrahydrofolate, further growth in the presence of folic acid led to a reduction in drug polyglutamylation due to an expanded folate pool, compared to growth in folate-free conditions. 42 Similarly, expansion of the folate pool in CEM R0/E45K cells when grown in folate-replete media, mediated by increased transport of folic acid, is likely to contribute to the observed reduction in MTX polyglutamylation in E45K hRFC overexpressing cells.
The clustering of mutations within the first transmembrane domain of the RFC protein in antifolate-resistant cell lines derived in vitro, suggests that this region may be important in mediating clinical response to MTX. Furthermore, the frequent occurrence of the E45K mutation, which is within this transmembrane spanning region, among a number of unique cell culture models selected for antifolate resistance using different conditions and derived from different species 16, 19, 22, 23 suggests that this alteration may especially be important clinically, such as with childhood ALL for which MTX is an essential component of chemotherapy protocols. In this instance, E45K would likely confer a significant survival advantage for lymphoblasts that express this gene variant, for an increased cellular uptake of serum folates would be protective in the presence of high doses of MTX. However, our analysis of 101 diagnosis ALL specimens and 20 samples obtained from patients at relapse failed to detect any mutation in the entire first transmembrane domain of the hRFC. Thus, in spite of this relatively small number of relapse samples, there is no indication that either the E45K or any other mutation in the first transmembrane domain contributes in any significant way to MTX resistance in childhood ALL. This example serves to highlight the problems when attempting to extrapolate results with highly drug-resistant cell culture models to clinical resistance. Although the E45K mutation may occur at high fre-
Figure 5
Analysis of the E45K hRFC gene mutation in relapsed leukemia specimens. pcDNA3/RFC-E45K plasmid DNA (lane 1), and cDNA from CEM/MTX R (lanes 2 and 3) cells, relapsed patient bone marrow specimens (lanes 4-12) and CCRF-CEM (lane 13) cells was PCR-amplified and digested with XmnI. Undigested CEM/MTX R (lane 2) PCR product was included as a negative control. quencies in cells selected for MTX and grown in high levels of exogenous folates, it remains to be determined what, if any, hRFC mutations are selected for in cells grown under physiological concentrations of folates and treated with pharmacologic doses of antifolates.
In conclusion, we have compared the functional properties and metabolic effects of the E45K mutation in hRFC with wildtype hRFC by their expression in an isogenic human leukemia cell model. Although E45K hRFC has dramatic effects on resistance to antifolates in human leukemia cells, our kinetic analysis in human transfectants demonstrates that there was only a comparatively minor change in the affinity for MTX and on the rate of membrane transport, even though the observed efficiency of transport was significantly reduced. By contrast, inhibition constants and growth requirements were markedly decreased for both folic acid and 5-formyl tetrahydrofolate, and a striking increase in transport of folic acid was observed compared to cells expressing the wild-type carrier. Thus, while overall transport efficiency by E45K hRFC is significantly reduced, MTX resistance in E45K hRFC expressing cells is further exacerbated by an increased transport of folic acid that significantly contributes to antifolate resistance, presumably due to direct competition for binding at their intracellular enzyme targets and/or conversion to the antifolate polyglutamyl forms. However, despite the frequency with which the E45K mutation has been observed in laboratory-derived MTXresistant cell lines, no evidence of this mutation was detected in a large cohort of primary ALL samples. Further studies are necessary to understand the extent to which mutations in the hRFC gene contribute to clinical MTX resistance.
